Open AccessThe Clinical and Economic Benefit of CMV Matching in Kidney Transplant: A Decision Analysis
Author(s) -
David A. Axelrod,
SuHsin Chang,
Krista L. Lentine,
Mark A. Schnitzler,
Doug Norman,
Ali J. Olyaei,
Darren Malinoski,
Vikas R. Dharnidharka,
Dorry L. Segev,
Gregory R. Istre,
Joseph B. Lockridge
Publication year - 2022
Publication title -
transplantation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.45
H-Index - 204
eISSN - 1534-6080
pISSN - 0041-1337
DOI - 10.1097/tp.0000000000003887
Subject(s) - medicine , cytomegalovirus , receipt , kidney transplantation , kidney transplant , betaherpesvirinae , human cytomegalovirus , kidney , intensive care medicine , virus , viral disease , immunology , herpesviridae , world wide web , computer science
The development of cytomegalovirus (CMV) infection after kidney transplant remains a significant cause of posttransplant morbidity, graft loss, and mortality. Despite appropriate antiviral therapy, recipients without previous CMV exposure can currently be allocated a kidney from a donor with previous CMV infection (D+R-) that carries the greatest risk of posttransplant CMV infection and associated complications. Preferential placement of CMV D- organs in negative recipients (R-) has been shown to reduce the risk of viral infection and associated complications.